The Global Protein Expression Systems Market, By Expression System (Mammalian Expression Systems, Insect Expression Systems, Bacterial Expression Systems, Plant Expression Systems, Yeast Expression Systems, and Cell Free Expression Systems), By Product Type (Competent Cells, Instruments, Reagents, and Others), By Application (Protein Therapeutics and Research Studies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
was valued at US$ 1.2 billion
in 2017, and is projected to exhibit a CAGR of 11.1%
over the forecast period (2018 - 2026), as highlighted in a new report published by .
The production of proteins in appropriate quantity and quality is an essential requirement of the biopharmaceutical and biotechnology industry. Therapeutic proteins provide important therapies for a variety of diseases such as anemia, diabetes, cancer, infectious diseases, and hemophilia. There is a growing demand for recombinant proteins for therapeutic applications. Common therapeutic proteins include antibodies, anticoagulants, hormones, FC fusion proteins, interleukins, and enzymes. Human proteins obtained through genetic engineering play a crucial role in therapeutic medicines.
Currently, most of all recombinant therapeutic proteins are produced in mammalian cells, mammalian cells are capable of producing high-quality proteins similar to the naturally occurring ones. Furthermore, many approved recombinant therapeutic proteins are generated in E. coli. (Bacteria) due to its well-characterized genetics, rapid growth, and high-yield production.
Pharmaceutical companies are progressively focusing on research using proteins to develop novel effective therapeutics. Advances in molecular control of gene expression are also expanding the opportunities for protein expression systems. The next generation expression systems are gaining traction as drug manufacturers are looking for cheaper ways to express new biologic drugs. For instance, on 6 December 2018, AMSBIO introduced ALiCE, a new high-yield cell-free protein expression system. ALiCE is a unique eukaryotic system, which yields an unprecedented 3 mg/ml of protein in batch mode.
Browse 25 Market Data Tables and 27 Figures spread through 164 Pages and in-depth TOC on "Protein Expression Systems Market, By Expression System (Mammalian Expression Systems, Insect Expression Systems, Bacterial Expression Systems, Plant Expression Systems, Yeast Expression Systems, and Cell Free Expression Systems), By Product Type (Competent Cells, Instruments, Reagents, and Others), By Application (Protein Therapeutics, and Research Studies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to protein expression systems market, click the link below:
Key Takeaways of the Protein Expression Systems Market:
- The global protein expression systems market is expected to expand at a CAGR of 11.1% during the forecast period (2018–2026), owing to increasing demand for protein therapeutics.
- Among expression system, the mammalian expression systems segment is expected to generate significant revenue in 2018. The major advantage to this system is that the antibody will be as close to native structure as possible, giving the highest possibility of proper binding activity.
- Major players operating in the global protein expression systems market include Agilent Technologies, Inc., Becton, Dickinson & Company, Lonza Group Ltd., GenScript Biotech Corporation, Bio-Rad Laboratories, Inc., Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., Takara Bio Inc., Synthetic Genomics Inc., Lucigen Corporation, Promega Corporation, ARTES Biotechnology GmbH, ProteoGenix, Addgene Inc., Geneva Biotech, Profacgen, and Peak Proteins Ltd.